International Survey from Biogen Identifies Opportunities for Improving MS Treatment Satisfaction
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Baird Remains Buyers of Biogen (BIIB) Despite Kyle Bass Tecfidera Challenge
April 22, 2015 3:50 PM EDTBaird analyst Christopher Raymond weighed in on Biogen (NASDAQ: BIIB) this afternoon following news hedge fund manager Kyle Bass has filed an IPR against a Tecfidera patent.
The analyst said the challenge does not come as a surprise and they predicted this in February after... More
Kyle Bass files challenge to Biogen (BIIB) patent on Tecfidera - Bloomberg
April 22, 2015 11:13 AM EDTKyle Bass files challenge to Biogen (NASDAQ: BIIB) patent on Tecfidera - Bloomberg
... More